Wednesday, May 11, 2011
Talon Therapeutics Inc., of San Mateo, Calif., began a Phase III trial of Marqibo (vincristine sulfate liposomes injection) for non-Hodgkin lymphoma. The study will be carried out by the German High-Grade non-Hodgkin lymphoma study group (DSHNHL). The trial will enroll 1,000 patients 61-80 years of age, and patient treatment will begin in the third quarter.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.